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1. Introduction
Advanced liver fibrosis results in cirrhosis, liver failure and 
portal hypertension. Liver transplantation is often needed 
for patients with end-stage liver disease, including collagen, 
Liver fibrosis is the excessive accumulation of extra-cellular 
matrix proteins that occurs in most types of chronic liver 
diseases. With the research in recent years, the knowledge 
of the cellular and molecular mechanisms of liver fibrosis 
has greatly advanced. Activated hepatic stellate cells, portal 
fibroblasts, myofibroblasts, bone marrow cells have been 
identified as major collagen-producing cells in the injured 
liver [1].
2. Historical perspective
Hepatic fibrosis was thought to be a passive and irreversible 
process due to the collapse of hepatic parenchyma and 
its substitution with a collagen-rich tissue in history. 
Currently, it is considered as a model of the wound-healing 
response to chronic liver injury. Rapid and slower fibrosis 
were identified, and genetic and environmental factors 
influencing fibrosis progression were partially uncovered. 
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   The main causes of liver fibrosis in industrialized 
countries include chronic HBV infection, chronic HCV 
infection, alcohol abuse and nonalcoholic steatohepatitis 
(NASH). Previous studies considered the accumulation 
of ECM proteins, which results in chronic damage to the 
liver, which is a characteristic of most types of chronic 
liver diseases. The accumulation of ECM proteins distorts 
the hepatic architecture by forming a fibrous scar, and 
the subsequent development of nodules of regenerating 
hepatocytes defines cirrhosis.  Cirrhosis produces 
hepatocellular dysfunction and increased intrahepatic 
resistance to blood flow, resulting in hepatic insufficiency 
and portal hypertension, respectively [2−4].
3. Natural history and diagnosis
The onset of liver fibrosis is usually insidious, and most 
of the related morbidity and mortality occur after the 
development of cirrhosis. In the majority of patients, 
progression to cirrhosis occurs after an interval of 15–20 
years. Major clinical complications of cirrhosis include 
ascites, renal failure, hepatic encephalopathy, and variceal 
bleeding. Patients with cirrhosis can remain free of major 
complications for several years (compensated cirrhosis). 
Decompensated cirrhosis is associated with short survival, 
and liver transplantation is often the only effective therapy. 
Cirrhosis is also a risk factor for developing hepatocellular 
carcinoma [5]. 
4. Pathogenesis of liver fibrosis
Hepatic fibrosis is the result of the wound-healing response 
of the liver to repeated injury. After an acute liver injury, 
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ABSTRACT: The occurrence of hepatic fibrosis is a multi-factor involved process. The 
key is the activation of hepatic stellate cells (HSC). Synthesis of extracellular matrix 
in the liver cells increases while degradation decreases. This paper reviews the tissue 
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parenchymal cells regenerate and replace the necrotic 
or apoptotic cells. This process is associated with an 
inflammatory response and a limited deposition of ECM. If 
the hepatic injury persists, eventually the liver regeneration 
fails, and hepatocytes are substituted with abundant ECM, 
including fibrillar collagen. The distribution of this fibrous 
material depends on the origin of the liver injury. In 
chronic viral hepatitis and chronic cholestatic disorders, 
the fibrotic tissue is initially located around portal tracts, 
while in alcohol-induced liver disease, it locates in 
pericentral and perisinusoidal areas. With the progress 
of fibrotic liver diseases, disease progresses from collagen 
bands to bridging fibrosis to cirrhosis occurs. Hepatic 
cell types other than HSCs may also have fibrogenic 
potential. Myofibroblasts derived from small portal vessels 
proliferate around biliary tracts in cholestasis-induced 
liver fibrosis to initiate collagen deposition. HSCs and 
portal myofibroblasts differ in specific cell markers and 
response to apoptotic stimuli. CD34+ CD38- hematopoietic 
stem cells with various growth factors have been shown to 
generate HSCs and myofibroblasts of bone marrow origin 
that infiltrate human livers tissue remodeling. These data 
suggest that cells originating in bone marrow can be a 
source of fibrogenic cells in the injured liver. The relative 
importance of each cell type in liver fibrogenesis may 
depend on the origin of the liver injury [6,9]. 
   Liver fibrosis is associated with major alterations in both 
the quantity and composition of ECM. In advanced stages, 
the liver contains approximately 6 times or above of ECM 
than normal, including collagens, fibronectin, elastin, 
laminin, hyaluronan, and proteoglycans. Accumulation 
of ECM results from both increased synthesis and 
decreased degradation. Decreased activity of ECM-
removing MMPs is mainly due to an overexpression of 
their specific inhibitors (TIMPs). HSCs are the main 
ECM-producing cells in the injured liver. In the normal 
liver, HSCs reside in the space of Disse and are the major 
storage sites of vitamin A. Following chronic injury, HSCs 
activate or transdifferentiate into myofibroblast-like cells, 
acquiring contractile, proinflammatory, and fibrogenic 
properties Activated HSCs migrate and accumulate 
at the sites of tissue repair, secreting large amounts of 
ECM and regulating ECM degradation. PDGF, mainly 
produced by Kupffer cells, is the predominant mitogen for 
activated HSCs. Collagen synthesis in HSCs is regulated 
at the transcriptional and post-transcriptional levels. 
Increased collagen mRNA stability mediates the increased 
collagen synthesis in activated HSCs. In these cells, post-
transcriptional regulation of collagen is governed by 
sequences in the 3’ untranslated region via the RNA-
binding protein CP2 as well as a stem-loop structure in the 
5’ end of collagen mRNA. Quiescent HSCs express markers 
that are characteristic of adipocytes (PPAR, SREBP-1c, and 
leptin), while activated HSCs express myogenic markers 
(smooth muscle actin, c-myb, and myocyte enhancer 
factor-2) [7,8].
5. Key cytokines involved in liver fibrosis
Cytokines regulate the inflammatory response to injury 
modulate hepatic fibrogenesis in vivo  and in vitro . 
Monocyte chemotactic protein type 1 and RANTES 
stimulate fibrogenesis while IL-10 and IFN exert have the 
opposite effect. Among growth factors, TGF-β1 appears 
to be a key mediator in human fibrogenesis. HSCs, 
TGF-β1 favors the transition to myofibroblast-like cells, 
stimulates the synthesis of ECM proteins, and inhibits their 
degradation. PDGF is the most potent mitogen for HSCs 
and is rised in the fibrotic liver; its inhibition attenuates 
experimental liver fibrogenesis. Adipokines, which are 
cytokines mainly derived from the adipose tissue, regulate 
liver fibrogenesis. Leptin is required for HSC activation and 
fibrosis development. In contrast, adiponectin markedly 
inhibits liver fibrogenesis in vitro and in vivo. The actions 
of these cytokines may explain why obesity influences 
fibrosis development in patients with chronic hepatitis C 
[10].
   Cytokines with vasoactive properties also regulate liver 
fibrogenesis. Vasodilator substances (such as nitric oxide, 
relaxin) exert antifibrotic effects while vasoconstrictors 
(such as norepinephrine, angiotensin II) have opposite 
effects. Endothelin-1, a powerful vasoconstrictor, 
stimulates fibrogenesis through its type A receptor in 
vasoactive cytokines, angiotensin II seems to play a major 
role in liver fibrogenesis. Angiotensin II is the effector 
peptide of the renin-angiotensin system, which is a major 
regulator of arterial pressure homeostasis in humans. 
Key components of this system are locally expressed in 
chronically injured livers, and activated HSCs generate 
angiotensin II importantly, pharmacological and/or 
genetic ablation of the renin-angiotensin system markedly 
attenuates experimental liver fibrosis. Angiotensin II 
induces hepatic inflammation and stimulates an array 
of fibrogenic actions in activated HSCs, including cell 
proliferation, cell migration, secretion of proinflammatory 
cytokines, and collagen synthesis. Unlike the phagocytic 
type, NADPH oxidases present in fibrogenic cell types 
are constitutively active, producing relatively low levels of 
ROS under basal conditions and generating higher levels 
of oxidants in response to cytokines, stimulating redox-
sensitive intracellular pathways. NADPH oxidase also 
plays a key role in the inflammatory actions of Kupffer cells 
[11,12].
6. Conclusion and future directions
Fibrosis is an excessive wound healing response that 
occurs in most forms of chronic liver disease and results 
in the deposition of scar tissue, i.e., excess extracellular 
matrix (ECM). With ongoing liver damage, fibrosis may 
progress to cirrhosis, which is characterized by a distortion 
of the liver vasculature and architecture, and is the major 
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determinant of morbidity and mortality in patients with 
liver disease. However, many patients either do not respond 
to causal treatment or are diagnosed with advanced fibrosis 
or cirrhosis. Because fibrosis and especially cirrhosis 
are the major predictors of liver-related morbidity and 
mortality, there is an urgent need to develop, test, and 
monitor antifibrotic treatments, in order to prevent, halt, 
or even reverse liver fibrosis or cirrhosis. Although we 
have made impressive progress in our understanding of 
the mechanisms based on the pathogenesis of liver fibrosis 
in the past two decades, translation of this knowledge into 
antifibrotic therapies has ground to a halt short of clinical 
trials.
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